Gilde raises additional capital for healthcare service investments - Gilde Healthcare

Gilde raises additional capital for healthcare service investments

October 13, 2011

Utrecht – Gilde Healthcare Partners has raised more than €50 million for its Gilde Healthcare Services fund. The fund invests growth capital in specialist clinics, elderly care, primary care, disease prevention, mental health, service laboratories and other healthcare service sectors.

“Innovative, expanding healthcare companies are in need of capital investment to support growth and this type of finance is often difficult to source from banks and governments in the current economic climate”

says Managing Partner Pieter van der Meer.

“As a value added partner providing growth capital Gilde can support the growth of various healthcare services companies.”, according to Jasper van Gorp, partner of the fund, “We are particularly focused on companies that provide quality care in a cost effective way.”

In 2010, the Gilde Healthcare Services fund invested in Stepping Stones Home & Care, a chain of small scale nursing homes for the elderly. The fund expects to announce an additional new investment in the coming weeks.

The fund complements existing Gilde Healthcare funds, which invest in companies developing medicines, diagnostic products and medical devices.

Gilde Healthcare company Lumicks secures €20 Million from European investment bank to accelerate drug discovery

Amsterdam-based LUMICKS signs €20 million venture debt with EIB to accelerate the development and launch of its new product, designed to advance immunotherapy development for cancer research. LUMICKS’ next generation high-throughput cell avidity platform aims...
October 10, 2024

Gilde Healthcare co-leads in an oversubscribed £80 million Series B financing in Purespring Therapeutics

Funds raised will support Purespring in advancing its AAV pipeline of gene therapy programmes to treat kidney disease, including its lead programme targeting IgA Nephropathy (IgAN) Round brings in new biotech investors, Gilde Healthcare, Sofinnova...
October 9, 2024

Gilde Healthcare company Adcendo announces IND clearance by FDA for the phase I/II study of ADCE-D01

ADCE-D01 is a first-in-class antibody-drug conjugate (ADC) targeting uPARAP, an endocytic receptor which is highly overexpressed in mesenchymal cancers including multiple soft tissue sarcoma (STS) subtypes The Phase I/II ADCElerate-01 trial is designed to evaluate...
October 8, 2024